Madrigal Pharmaceuticals (MDGL) Short term Debt (2010 - 2016)

Madrigal Pharmaceuticals (MDGL) has reported Short term Debt for 7 consecutive years, with $10000.0 the latest figure, recorded in Q2 2016.

• In Q2 2016, Short term Debt fell 99.89% year-over-year to $10000.0; the TTM figure through Jun 2016 stood at $10000.0 (down 99.89% YoY), while the FY2015 annual figure was $4.6 million, down 50.0% from the prior year.
• Short term Debt fell to $10000.0 in Q2 2016 per MDGL's latest filing, from $2.3 million in the prior quarter.
• Across five years, Short term Debt topped out at $9.5 million in Q4 2013 and bottomed at $10000.0 in Q2 2016.
• Historically, Short term Debt has averaged $6.9 million across 5 years, with a median of $7.9 million in 2012.
• Annual changes were most pronounced in 2014 — Short term Debt jumped 200.58% — and 2016, when it sank 99.89%.
• Madrigal Pharmaceuticals' Short term Debt stood at $7.9 million in 2012, then climbed by 19.27% to $9.5 million in 2013, then fell by 2.51% to $9.2 million in 2014, then slumped by 50.0% to $4.6 million in 2015, then slumped by 99.78% to $10000.0 in 2016.
• Business Quant data shows MDGL's Short term Debt at $10000.0 in Q2 2016, $2.3 million in Q1 2016, and $4.6 million in Q4 2015.